Retatrutide in published trial literature

Research-use notice: This article is laboratory and educational information only. It is not medical or legal advice, and it does not include how-to-use instructions. BlueNex Labs materials are research-use only and are not intended for human or veterinary use. Research-use-only labeling is not a Health Canada authorization.

Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly. It is described as a triple agonist at GLP-1, GIP, and glucagon receptors. As of the status check for this article it is not FDA-approved and is not a Health Canada-authorized medicine. This page summarizes how public trial programmes are discussed in the literature. It is not a shop listing and it is not medical advice.

How this molecule is classified in papers

Semaglutide is typically discussed as a GLP-1 receptor agonist. Tirzepatide is discussed as a dual GIP and GLP-1 agonist. Retatrutide is discussed as adding glucagon-receptor activity to that dual-incretin pattern. Those labels are receptor-class descriptions. They are not instructions for people and they are not claims that a research vial equals a trial drug.

What registered studies are designed to measure

Public registries and sponsor communications describe programmes that record glycemic markers, body-composition or body-weight endpoints, and safety in defined cohorts. Phase numbering (1, 2, 3) refers to those clinical programmes. Reporting a trial endpoint is not the same as advertising a consumer outcome. For regulatory status and the TRIUMPH name, see Retatrutide FDA status and TRIUMPH trial timeline. For a late-stage diabetes readout recap see the research-news note.

What this page does not do

It does not rank products, compare vial prices, or tell anyone how to use a peptide. Neighboring incretin names in the catalog are separate SKUs with separate lots. Class overviews also live in GLP-1 peptide research in 2026.

Related catalog documentation

If you need vial sizes and batch reports, open the retatrutide catalog listing and the retatrutide COA section. 10 mg, 20 mg, and 30 mg fills are different lots when both exist. Research-use only — not for human or veterinary use.